血清lncRNA DLX6-AS1 Actinin-4表达与宫颈癌术后复发及预后的关系

doi:10.3969/j.issn.1006-6233.2022.10.021

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1330 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的: 研究宫颈癌患者血清长链非编码RNA(Long non-coding RNA,lncRNA)DLX6-AS1、辅肌动蛋白4(Actinin-4)表达与宫颈癌根治术后复发及预后的关系。方法: 选取自2016年2月至2018年2月期间行宫颈癌根治术的120例宫颈癌患者为研究对象(宫颈癌组),以同期健康体检的50例健康人为对照组。宫颈癌组根据术后3年肿瘤复发进展情况,分为无复发组(101例)及复发组(19例)。采用荧光实时定量聚合酶链反应法检测血清lncRNA DLX6-AS1表达,采用酶联免疫吸附实验检测血清Actinin-4表达。分析血清lncRNA DLX6-AS1、Actinin-4表达水平与宫颈癌患者临床病理特征的关系。随访3年,采用Kaplan-Meier生存分析分析血清lncRNA DLX6-AS1、Actinin-4表达与宫颈癌患者术后预后差异。分析影响宫颈癌患者术后复发的因素。结果: 与对照组相比,宫颈癌组血清lncRNA DLX6-AS1、Actinin-4表达显著升高(P<0.05)。Pearson相关分析结果,宫颈癌组血清lncRNA DLX6-AS1与Actinin-4的表达呈显著正相关性(r=0.560、P=0.000)。不同FIGO分期、病理分级、间质浸润深度及淋巴结转移患者血清lncRNA DLX6-AS1、Actinin-4表达差异具有统计学意义(P<0.05)。lncRNA DLX6-AS1高表达组、Actinin-4高表达组3年无进展生存率及无进展生存时间均低于低表达组(均P<0.05)。病理分级低分化、FIGO分期ⅡA期、lncRNA DLX6-AS1高表达、Actinin-4高表达是影响宫颈癌根治术术后复发的独立危险因素(均P<0.05)。结论: 宫颈癌患者血清lncRNA DLX6-AS1、Actinin-4表达升高、两者的表达与宫颈癌术后复发有关、可能是新的预后判断的血清标志物。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：长链非编码RNA DLX6-AS1, 辅肌动蛋白4, 宫颈癌根治术, 复发

Abstract：Objective: To study the relationship between the expressions of serum long non-coding RNA (lncRNA) DLX6-AS1 and actinin-4 in patients with cervical cancer and their relationship with recurrence and prognosis after radical resection of cervical cancer. Methods: A total of 120 cervical cancer patients who underwent radical resection of cervical cancer from February 2016 to February 2018 were selected as the research subjects (cervical cancer group),and 50 healthy individuals who underwent physical examination during the same period were selected as the control group.The cervical cancer group was divided into non-recurrence group (101 cases) and recurrence group (19 cases) according to the tumor recurrence and progression 3 years after operation.The expression of serum lncRNA DLX6-AS1 was detected by fluorescence real-time quantitative polymerase chain reaction,and the expression of serum actinin-4 was detected by enzyme-linked immunosorbent assay.Statistical analysis was performed to compare the relationship between the expression levels of serum lncRNA DLX6-AS1,actinin-4 and the clinicopathological characteristics of cervical cancer patients.At 3 years follow-up,Kaplan-Meier survival analysis was used to analyse the difference between serum lncRNA DLX6-AS1 and actinin-4 expression and postoperative prognosis of cervical cancer patients.The factors affecting postoperative recurrence of cervical cancer patients were analyzed. Results: Compared with the control group,the expression of serum lncRNA DLX6-AS1 and actinin-4 in the cervical cancer group was significantly higher (P<0.05).Pearson correlation analysis showed that the expression of serum lncRNA DLX6-AS1 and Actinin-4 in the cervical cancer group showed a significant positive correlation (r = 0.560,P = 0.000).There were significant differences in serum lncRNA DLX6-AS1 and Actinin-4 expression between patients with different FIGO stages,pathological grades,depth of interstitial invasion and lymph node metastasis(P<0.05).The 3-year progression-free survival rate and progression-free survival time were lower in the lncRNA DLX6-AS1 high expression group and Actinin-4 high expression group than in the low expression group ( All P<0.05).The pathological grade of low differentiation,FIGO stage IIA,high expression of lncRNA DLX6-AS1 and high expression of Actinin-4 were independent risk factors for recurrence of cervical cancer after radical cervical surgery (all P<0.05). Conclusion: Increased expression of serum lncRNA DLX6-AS1 and Actinin-4 in patients with cervical cancer is associated with postoperative recurrence of cervical cancer and may be a new serum marker for prognosis.

Key words： Long non-coding RNA DLX6-AS1 Actinin 4 Radical surgery for cervical cancer Recurrence

基金资助:山西省卫生健康科研课题,(编号:2019049)

引用本文:

刘贵珍, 杨瑞红, 李宝连. 血清lncRNA DLX6-AS1 Actinin-4表达与宫颈癌术后复发及预后的关系[J]. 河北医学, 2022, 28(10): 1689-1695.
LIU Guizhen, et al. Association of Serum lncRNA DLX6-AS1 and Actinin-4 Expression with Recurrence and Prognosis of Cervical Cancer after Surgery. HeBei Med, 2022, 28(10): 1689-1695.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2022.10.021 或 http://www.hbyxzzs.cn/CN/Y2022/V28/I10/1689

[1] 王瑾瑶,张年萍,白志强,等.1993年至2017年中国宫颈癌发病率和死亡率长期趋势的年龄-时期-队列模型分析[J].中国全科医学,2022,25(13):1564-1568.
[2] Small W,Bosch W R,Harkenrider M M,et al.NRG oncology/RTOG consensus guidelines for delineation of clinical target volume for intensity modulated pelvic radiation therapy in postoperative treatment of endometrial and cervical cancer:an update[J].Int Radiat Oncol Biol Phys,2021,109(2):413-424.
[3] Wang H,Niu X,Jiang H,et al.Long non-coding RNA DLX6-AS1 facilitates bladder cancer progression through modulating miR-195-5p/VEGFA signaling pathway[J].Aging (Albany NY),2020,12(16):16021-16034.
[4] Fang C,Li J,Deng T,et al.Actinin-4 as a diagnostic biomarker in serum of breast cancer patients[J].Med Sci Monit,2019,25(7):3298-3302.
[5] Park S,Kang M,Kim S,et al.α-actinin-4 promotes the progression of prostate cancer through the Akt/GSK-3β/β-catenin signaling pathway[J].Front Cell Dev Biol,2020,8(7):5885-5864.
[6] Xu Y,Zhang M,Zhang J,et al.Neoadjuvant chemotherapy increases the 5-year overall survival of patients with resectable cervical cancer:a systematic review and meta-analysis[J].Taiwan Obstet Gynecol,2021,60(3):433-441.
[7] 阿曼古丽,王英红.LncRNA SRA在宫颈癌患者血清中的表达及与预后的关系[J].中国妇产科临床杂志,2020,21(3):304-305.
[8] Zhao X,Wang J,Zhu R,et al.DLX6-AS1 activated by H3K4me1 enhanced secondary cisplatin resistance of lung squamous cell carcinoma through modulating miR-181a-5p/miR-382-5p/CELF1 axis[J].Sci Rep,2021,11(1):2101-2110.
[9] Xie F,Xie G,Sun Q.Long noncoding RNA DLX6-AS1 promotes the progression in cervical cancer by targeting miR-16-5p/ARPP19 axis[J].Cancer Biother Radiopharm,2020,35(2):129-136.
[10] Tian Y,Wang Y,Jia S.Knockdown of long noncoding RNA DLX6-AS1 inhibits cell proliferation and invasion of cervical cancer cells by downregulating FUS[J].Eur Rev Med Pharmacol Sci,2020,24(19):9771-9779.
[11] Zhao Z,Liang S,Sun F.LncRNA DLX6-AS1 promotes malignant phenotype and lymph node metastasis in prostate cancer by inducing LARGE methylation[J].Front Oncol,2020,10(7):1172-1179.
[12] Wang Q,Qin Q,Song R,et al.NHERF1 inhibits beta-catenin-mediated proliferation of cervical cancer cells through suppression of alpha-actinin-4 expression[J].Cell Death Dis,2018,9(6):668-674.
[13] Sugano T,Yoshida M,Masuda M,et al.Prognostic impact of ACTN4 gene copy number alteration in hormone receptor-positive,HER2-negative,node-negative invasive breast carcinoma[J].Br Cancer,2020,122(12):1811-1817.
[14] Jung J,Kim S,An H,et al.α-Actinin-4 regulates cancer stem cell properties and chemoresistance in cervical cancer[J].Carcinogenesis,2020,41(7):940-949.
[15] Su W,Shen Y,Wang Y,et al.circPHIP promotes oral squamous cell carcinoma progression by sponging miR-142-5p and regulating PHIP and ACTN4 expression[J].Mol Ther Nucleic Acids,2020,23(7):185-199.